About Us
Dedicated to the discovery
and development of
targeted anti-cancer therapeutics
About Us

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. 


 
IMPACT pipeline products include PARP inhibitor (senaparib/ IMP4297), Wee1 inhibitor (IMP7068), and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China. 


 
Established and operated by an experienced management team in the pharmaceutical industry globally, the company has established a fully functional discovery and clinical development organization which expands to the United States. The company has received investment from recognized venture capital firms such as Lilly Asia Ventures as well as a strategic investor JunShi Biosciences.

Our Story
Explore, innovate and forge ahead
2021
2020
2019
2018
2017
2015
2014
Our Culture
Strive to improve the life of patients


IMPACT Therapeutics pursues innovation and create new cancer treatments by unlocking the potential of synthetic lethality. With the scientist spirit, we continue to break new ground as we explore the unlimited possibilities of targeted anti-cancer therapy.


IMPACT Therapeutics respects life above all else. Our dedication to protecting life and meeting the needs of patients drives us to overcome challenges, act decisively, and promote the development of innovative drugs. Our commitment to development enables us to improve the quality of life for our patients.


We all come from diverse backgrounds and have different experiences, but we have gathered here because we share the same drive and beliefs. We are IMPACT Therapeutics.
Management Team
  • Dr. Jun Bao
    President & CEO
  • Dr. Ye Edward Tian
    Executive Vice President & Chief Scientific Officer
  • Dr. Sui Xiong Cai
    Executive Vice President & Chief Technical Officer
  • Dr. Chih-Yi Hsieh
    Senior Vice President & Chief Medical Officer
Dr. Jun Bao

Dr. Jun Bao, President & CEO, with more than 20 years of comprehensive experience in the production and research, extensive experience in drug research and development, technology transfer, licensing and business development, venture investment, entrepreneurship and corporate finance. Before IMPACT Therapeutics, he was SVP & CBO at Shenogen Pharma. He also worked as Director of corporate development and financial planning in Onyx followed by Director of Worldwide BD & Head of China BD in GSK. Moreover, in Seattle, he worked at ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities.

 

 

President & CEO

Dr. Ye Edward Tian

Dr. Ye Edward Tian, EVP & CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI. Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University.

 

 

Executive Vice President & Chief Scientific Officer

Dr. Sui Xiong Cai

Dr. Sui Xiong Cai, EVP & CTO, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials. He is an inventor of more than 90 issued patents and he received his PhD in Organic Chemistry from University of Oregon.

 

 

Executive Vice President & Chief Technical Officer

Dr. Chih-Yi Hsieh

Dr. Chih-Yi Hsieh, MD, owns over ten years’ experiences in oncology clinic and global clinical trials. He was the Chief Medical Officer in ASLAN Pharmaceuticals, leading and completing multiple multinational and single-country clinical trials ranging from phase 1 to global pivotal studies. Prior to that, Dr. Hsieh was Medical Advisor at Novartis Oncology and attending physician in the Taoyuan branch, Taipei Veterans General Hospital. Dr. Chih-Yi Hsieh holds an MD degree from the National Yang-Ming University, Taiwan, and specialist qualifications in Internal Medicine, Medical Oncology, Hematology, and in Blood and Marrow Transplantation.

 

 

Senior Vice President & Chief Medical Officer

Scientific Advisors
Contact Us
Sincerely welcome you
  • 021-68411121
  • info@impacttherapeutics.com
  • 12th Floor, New Bund Times Square, 399 Haiyang West Road, Pudong New Area, Shanghai, China
  • 025-52283667
  • info@impacttherapeutics.com
  • Room 2506, Jingfeng Center, No. 1698 Shuanglong Avenue, Jiangning District, Nanjing